Par Drugs and Chemicals Limited

NSEI:PAR Lagerbericht

Marktkapitalisierung: ₹3.8b

Par Drugs and Chemicals Zukünftiges Wachstum

Future Kriterienprüfungen 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Par Drugs and Chemicals.

Wichtige Informationen

n/a

Wachstumsrate der Gewinne

n/a

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum18.4%
Wachstumsrate der Einnahmenn/a
Zukünftige Eigenkapitalrenditen/a
Analystenabdeckung

None

Zuletzt aktualisiertn/a

Jüngste Aktualisierungen zum künftigen Wachstum

Keine Aktualisierungen

Recent updates

There's No Escaping Par Drugs and Chemicals Limited's (NSE:PAR) Muted Earnings Despite A 26% Share Price Rise

Oct 29
There's No Escaping Par Drugs and Chemicals Limited's (NSE:PAR) Muted Earnings Despite A 26% Share Price Rise

Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified

Apr 16
Improved Earnings Required Before Par Drugs and Chemicals Limited (NSE:PAR) Stock's 29% Jump Looks Justified

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Apr 05
Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?

Nov 03
Do Par Drugs and Chemicals' (NSE:PAR) Earnings Warrant Your Attention?

If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity

May 19
If EPS Growth Is Important To You, Par Drugs and Chemicals (NSE:PAR) Presents An Opportunity

Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?

Mar 17
Does Par Drugs and Chemicals (NSE:PAR) Deserve A Spot On Your Watchlist?

Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?

Oct 22
Do Par Drugs and Chemicals's (NSE:PAR) Earnings Warrant Your Attention?

Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings

Aug 11
Investors Shouldn't Be Too Comfortable With Par Drugs and Chemicals' (NSE:PAR) Robust Earnings

Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching

Jul 14
Here's Why We Think Par Drugs and Chemicals (NSE:PAR) Is Well Worth Watching

Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?

Mar 31
Is Par Drugs and Chemicals Limited (NSE:PAR) An Attractive Dividend Stock?

Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?

Mar 05
Are Strong Financial Prospects The Force That Is Driving The Momentum In Par Drugs and Chemicals Limited's NSE:PAR) Stock?

Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)

Feb 06
Chairman of the Board & MD Falgun Savani Just Bought A Handful Of Shares In Par Drugs and Chemicals Limited (NSE:PAR)

Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

Jan 10
Here's Why I Think Par Drugs and Chemicals (NSE:PAR) Might Deserve Your Attention Today

How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?

Dec 13
How Does Par Drugs and Chemicals Limited (NSE:PAR) Fare As A Dividend Stock?

In diesem Abschnitt stellen wir normalerweise Umsatz- und Gewinnwachstumsprognosen vor, die auf den Konsensschätzungen professioneller Analysten basieren, um den Anlegern zu helfen, die Fähigkeit des Unternehmens zur Gewinnerzielung zu verstehen. Da Par Drugs and Chemicals jedoch nicht genügend Daten aus der Vergangenheit zur Verfügung gestellt hat und keine Analystenprognose vorliegt, können die zukünftigen Erträge nicht zuverlässig durch Extrapolation von Vergangenheitsdaten oder anhand von Analystenprognosen berechnet werden.

Dies ist eine recht seltene Situation, da 97 % der von SimplyWall St erfassten Unternehmen über Finanzdaten aus der Vergangenheit verfügen.

Gewinn- und Umsatzwachstumsprognosen

NSEI:PAR - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (INR Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
9/30/20241,041183145172N/A
6/30/2024953146N/AN/AN/A
3/31/2024956145142202N/A
12/31/2023973142N/AN/AN/A
9/30/2023962127140227N/A
6/30/2023952115N/AN/AN/A
3/31/202395711357134N/A
12/31/2022933103N/AN/AN/A
9/30/20228731063276N/A
6/30/202282191N/AN/AN/A
3/31/2022751924476N/A
12/31/2021692112N/AN/AN/A
9/30/2021686112467N/A
6/30/2021631115N/AN/AN/A
3/31/202160811670121N/A
12/31/202057988N/AN/AN/A
9/30/202055083102120N/A
6/30/2020554658298N/A
3/31/2020558486177N/A
12/31/201953241N/AN/AN/A
9/30/2019506201217N/A
6/30/2019484231519N/A
3/31/2019463253034N/A
3/31/201842415N/A46N/A
3/31/201748818N/A92N/A
3/31/20163334N/A65N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: Insufficient data to determine if PAR's forecast earnings growth is above the savings rate (6.7%).

Ertrag vs. Markt: Insufficient data to determine if PAR's earnings are forecast to grow faster than the Indian market

Hohe Wachstumserträge: Insufficient data to determine if PAR's earnings are expected to grow significantly over the next 3 years.

Einnahmen vs. Markt: Insufficient data to determine if PAR's revenue is forecast to grow faster than the Indian market.

Hohe Wachstumseinnahmen: Insufficient data to determine if PAR's revenue is forecast to grow faster than 20% per year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if PAR's Return on Equity is forecast to be high in 3 years time

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y